Celltrion to select lead antibody candidates to fight COVID-19
Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.
List view / Grid view
Following the screening of antibodies, Celltrion will now identify the most potent out of 300 hits that work against the COVID-19 coronavirus best.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
Researchers have demonstrated that Nafamostat mesylate (Fusan) can inhibit SARS-CoV-2 Spike protein-initiated membrane fusion at concentrations likely achievable and safe in patients.
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
Researchers are working to build a complete, all-atom model of the exterior of the coronavirus to aid in drug design.
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
A researcher has revealed that angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) may increase the risk of severe lung complications in COVID-19.
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
Using X-ray crystallography, researchers have revealed the structure of the SARS-CoV-2 main protease, designing an inhibitor to bind to this target and prevent viral replication.
Researchers reveal that a broad range of immune cells react to COVID-19 and aid recovery, findings which could inform the development of a potential vaccine.
Researchers have used cryogenic electron microscopy to show that coronaviruses enter human cells through an interaction with angiotensin-converting enzyme 2 (ACE2).
Using cryogenic electron microscopy, a team has mapped the Spike protein on COVID-19, which could be used in the development of vaccines.